Aldeyra Therapeutics Inc — Cash Flow (NASDAQ:ALDX) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities -37.49 M-42.56 M-56.64 M-30.33 M-43.21 M -40.08 M Cash from investing activities 29.02 M-7 806-29.95 M30 M-44.92 M 30.17 M Cash from financing activities 41.9 M194.5 M1.22 M-1.27 M-171.42 K 1.13 M Free cash flow -37.49 M-42.56 M-56.65 M-30.33 M-43.21 M -40.08 M

Nachrichten

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

BTIG-Analyse: Die Top-Picks im Gesundheitssektor für 2026/n

Top Healthcare Stocks for This Year According to BTIG

Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know

Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?

Aldeyra Therapeutics: Entwicklungsvorstand tritt bis März 2026 zurück

Aldeyra Therapeutics chief development officer to step down by March 2026

Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst

Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX)

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Adagio Medical Holdings (NASDAQ:ADGM), Aldeyra Therapeutics (NASDAQ:ALDX)

Prognose von InvestingPro: Überbewertete Aldeyra-Aktie bricht um 36 % ein

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye - Slideshow (NASDAQ:ALDX) 2025-11-16